We reviewed the literature and the manufacturer's U.S. clinical data pool for safety data on long-term administration of ciprofloxacin (Bayer, West Haven, CT). Only controlled clinical trials including patients treated for ú30 days were selected. We identified 636 patients by literature search and 413 patients in the Bayer U.S. database who fulfilled our search criteria; the average treatment duration for these patients was 130 and 80 days, respectively. Main indications for long-term therapy were osteomyelitis, skin and soft-tissue infection, prophylaxis for urinary tract infection, mycobacterial infections, and inflammatory bowel disease. Adverse events, premature discontinuation of therapy, and deaths occurred at a similar frequency in both treatment arms. Most adverse events occurred early during therapy with little increase in frequency over time. As with short-term therapy, gastrointestinal events were more frequent than central nervous system or skin reactions, but pseudomembranous colitis was not observed. No previously unknown adverse events were noted. We conclude that ciprofloxacin is tolerated as well as other antibiotics when extended courses of therapy are required.
Over the past 10 years, fluoroquinolones have proven their cially the use of pefloxacin in the presence of predisposing risk factors [16] . It would appear that certain members of the value as broad-spectrum antibiotics for oral and intravenous treatment of a wide variety of infections [1, 2] . Despite extenquinolone class of antibiotics exhibit distinct and occasionally unusual toxicity profiles [12, 13, 17 -20] . sive use and reports of emerging resistance of problematic organisms, these drugs continue to be highly efficacious therFrom a pharmacokinetic and toxicological perspective, drug safety is correlated to peak drug concentrations in serum and apy even for infections difficult to treat with other antibiotics [3 -5] .
cumulative exposure. On the basis of animal data, cartilaginous joints (vacuolization), eyes (cataract formation and retinal damFluoroquinolones are generally well tolerated [6, 7] . Most adverse events (AEs) involve the gastrointestinal tract and age), and kidneys (crystalluria and interstitial nephritis) are potential sites for organ toxicity with prolonged quinolone use CNS, while photosensitivity and drug interactions are less frequently reported [8 -12] . These side effects are often mild in [12, 21 -24] . Conceivably, prolonged outpatient therapy with quinolones may lead to a higher incidence of photosensitivity severity, self-limiting, and easily managed and rarely require discontinuation of therapy [13] . Severe or serious adverse reac- [25] .
There is conflicting and incomplete information on the relations associated with fluoroquinolones are rare and not disproportionately more frequent than those associated with other tionship between the frequency of AEs and the duration of quinolone therapy. Some investigators claim that lomefloxacin antibiotics [14] .
The recent recognition of a ''hemolytic-uremic''-like synand norfloxacin have a greater propensity to cause AEs with prolonged administration [2, 26, 27] ; however, this relationship drome after exposure to temafloxacin has renewed concerns about hitherto unknown but potentially dangerous idiosyncratic may not hold true for all quinolones [28] .
Although there are ample clinical data supporting the safety or toxic reactions associated with fluoroquinolone use [14, 15] . Likewise, the development of tendinopathy leading to tendon of ciprofloxacin when administered at daily doses of up to 1,500 mg for conventional treatment courses up to 3 weeks [7, rupture (an exceedingly rare AE with an estimated incidence rate of less than one in 10 6 treated cases) has only recently 29 -33] , less information is available on the tolerability of longterm therapy.
In this review, we analyze safety information for become known and linked to fluoroquinolone exposure, espeadult patients who participated in controlled trials and received ciprofloxacin therapy for ú30 days. We also present safety data from the manufacturer's clinical data pool in the United States. CID 1999; 28 (February) apy was administered for ú30 days. We used the search terms with ciprofloxacin and controls, respectively (tables 1 and 2). Duration of therapy with ciprofloxacin varied from 2 to 12 comparative trials, long-term, ciprofloxacin, prophylaxis, osteomyelitis, endocarditis, prostatitis, mycobacterial, and neumonths, with an average treatment period of 4.3 months. In 18 trials, ciprofloxacin was used as monotherapy. Nine studies tropenia and reviewed appropriate articles for further leads. Studies comparing different doses of ciprofloxacin and regiwere designed as double-blind trials, involving 266 ciprofloxacin recipients and 285 control recipients (table 1) . mens in which ciprofloxacin was not administered daily were not considered. Likewise, trials using repeated short-term treatIn 16 of 22 studies, treatment was given for established infections. Five of 16 studies were placebo-controlled. In 12 ment courses were excluded.
The Bayer (West Haven, CT) U.S. database of all phase 2 of these trials, ciprofloxacin was used as monotherapy. Ciprofloxacin was usually administered orally at doses of 500 to and phase 3 clinical trials was searched for studies that included at least one patient treated with ciprofloxacin (intravenously or 750 mg b.i.d., thus reflecting the severe nature of the infectious state or condition. Main indications for therapy were soft-tissue orally) and at least one patient treated with a control drug, each for ú30 days. All studies entered in the Bayer U.S. database infections and osteomyelitis, mycobacterial infections, and inflammatory bowel disease. through January 1997 were included in the search. The population used for the summary was all patients from these studies
In six of 22 trials, ciprofloxacin was given for daily longterm prophylaxis. The oral ciprofloxacin doses were much lower who were treated for ú30 days. Patients treated £30 days were excluded.
for this group (range, 100 to 250 mg q.d.). Prevention of urinary tract infection (UTI) in patients prone to develop recurrent infecReported studies rarely distinguish between AEs and adverse drug reactions (ADRs), often using these terms interchangeably tions caused by problem organisms was the main indication.
The type and frequency of AEs, premature discontinuations without clear definitions. Information on the severity, duration, and outcome of AEs, or their relationship to study drug, is also of therapy, and deaths reported in these trials are summarized in table 2. provided infrequently.
In contrast, all Bayer U.S. studies defined AEs as intercurrent Soft-tissue infections and osteomyelitis. These trials were generally designed to compare conventional long-term intraveillnesses experienced by the patient while receiving study drug and within 7 days after the end of therapy. Such treatmentnous antibiotic therapy with oral ciprofloxacin therapy [34 -41] . Although the comparator treatment regimens often conemergent events are not necessarily related to study drug. ADRs are a subset of AEs considered to be at least remotely related sisted of bactericidal antibiotics in combination, ciprofloxacin was predominantly used as monotherapy. A high dosage of to study drug. In all Bayer U.S. studies, reporting of AEs and ADRs was protocol-driven with use of uniform criteria and oral ciprofloxacin of 750 mg b.i.d. was employed in most of the six osteomyelitis studies and in two trials involving patients definitions for safety reporting. Severity of AEs was graded as mild, moderate, severe, or serious/life-threatening (see Appenwith chronic leg ulcers. Overall, AEs occurred less often with ciprofloxacin than with dix for full definitions).
For the purpose of this review, only data on premature discontrol antibiotics, even reaching statistical significance in one trial [39] . The incidence rates of AEs ranged from 3% to 29% continuation of therapy due to AEs are presented. among the ciprofloxacin-treated patients and from 0 to 54% among the control recipients. Although frequent in both groups,
Statistical Methods
AEs were not severe and mainly consisted of nausea, vomiting, dizziness, and abnormal values of liver function tests. CiFor analysis of the Bayer U.S. database, descriptive statistics profloxacin was associated with significantly fewer episodes were generated for demographic variables, incidence rates of of photosensitivity than was lomefloxacin (zero vs. five cases, AEs, premature discontinuations of therapy, and deaths. NOTE. AECB Å acute exacerbation of chronic bronchitis; Amik Å amikacin; Cm Å clindamycin; Cpfx Å ciprofloxacin; Ctri Å ceftriaxone; DB Å doubleblind; Eth Å ethambutol; Gm Å gentamicin; INH Å isoniazid; Lmfx Å lomefloxacin; MAC Å Mycobacterium avium complex; Mtz Å metronidazole; NA Å not available; Naf Å nafcillin; Ofx Å ofloxacin; PZA Å pyrazinamide; RC Å randomized, controlled; Rif Å rifampin; Stm Å streptomycin; SMZ Å sulfamethoxazole; TMP Å trimethoprim; UTI Å urinary tract infection.
/ 9c61$$fe49
01-20-99 14:59:58 cidal UC: CID In another double-blind, placebo-controlled study by Turunen et al. [47] , patients with ulcerative colitis were treated with hours after study therapy was started. A second seizure occurred 9 days later while she was still receiving therapy. After discontinlong-term ciprofloxacin therapy. Two patients (5%) developed deep-vein thrombosis, an AE probably unrelated to oral ciuation of all antituberculous therapy, benzylpenicillin treatment was initiated, but the patient continued to suffer convulsions and profloxacin use. None of the patients were withdrawn from the trial. died 27 days after admission. Determination of drug levels, brain imaging studies, and a postmortem examination were not perToivanen et al. [45] noted only rash and malaise in two of 17 patients with reactive arthritis treated with ciprofloxacin for formed to better define the cause of this patient's seizure disorder. Kennedy et al. [43] In a trial of prophylaxis for bronchitis [53] , one ciprofloxacin placebo to treatment with rifampin and ethambutol. Twelve patients in each group were treated for 8 weeks. AEs were recipient and three ciprofloxacin/erythromycin recipients developed laboratory-evident abnormalities that resolved after reported for 10 ciprofloxacin recipients (83%) vs. three placebo recipients (25%) (P Å .01). AEs included nausea, fever, anadiscontinuation of study therapy. No AEs seem to have occurred in patients with bronchitis treated with erythromycin phylactoid reaction, and adverse drug interaction (with methadone and digoxin). Drug-related AEs requiring discontinuation alone. of study medication occurred in nine ciprofloxacin recipients and one placebo recipient (P Å .005).
Bayer U.S. Data Pool

Inflammatory bowel disease and reactive arthritis. An autoimmune response to bacterial antigens has been postulated
Demographics. By January 1997, the Bayer U.S. database contained ú11,000 ciprofloxacin-treated cases from controlled for these chronic diseases of unknown etiology. In contrast to most other trials, ciprofloxacin was compared with placebo or clinical trials. Of these patients, 1,589 were treated uninterruptedly for ú30 days. We identified 18 clinical trials that fulfilled steroids not other antibiotics [45 -48] . The oral dosage was 500 mg b.i.d.; some patients received higher dosages of 750 our selection criteria. According to trial protocol, 339 patients received ciprofloxamg b.i.d. to adjust for body weight. A double-blind study design was used in three of four trials. cin as monotherapy, and an additional 74 patients were treated with ciprofloxacin in combination with another antibiotic ( trimethoprim-sulfamethoxazole, or vancomycin). Only nine paprofloxacin monotherapy group and 45 years in the control group. Most patients were white males in good to fair health tients in the control group received protocol-driven combination therapy with intravenous aminoglycosides (ceftazidime at the time of study entry. The average duration of therapy in the ciprofloxacin arm (81 days) was similar to that in the control plus amikacin or piperacillin plus tobramycin).
Long-term therapy was mainly employed for the treatment arm (79 days). In contrast, the mean age of the patients was higher (51 years) and the average treatment duration was of osteomyelitis and as prophylaxis for UTI in patients after renal transplantation. Other indications were severe skin and shorter (55 days) for the combination therapy group than for the other groups. Overall, male patients outnumbered female mixed soft-tissue infections, diabetic foot infections, staphylococcal infections, and neutropenic fever in the immunocompatients by a ratio of approximately 3:1.
AEs and drug-related AEs: frequency, severity, and outcome. promised host (table 3) .
The monotherapy treatment groups were well matched for AEs occurred at a similar frequency among the ciprofloxacin monotherapy group and the control treatment group (32% and sex, age, weight, ethnic background, and underlying health status. The mean age of the patients was 46 years in the ci-35%, respectively). Patients younger than 65 years of age expe-/ 9c61$$fe49 01-20-99 14:59:58 cidal UC: CID rienced AEs less often (32%) than did the group of patients 65 years of age or older (42%). A higher incidence rate of The number of AEs per patient was lower for the ciprofloxaAEs was observed among the group receiving ciprofloxacin cin monotherapy group (0.86) than for the other treatment combination therapy (55%) than among the other groups (table groups (1.18 and 1.93 in the control and ciprofloxacin combina-4). However, analysis of the subset of trials in which ciprofloxtion groups, respectively) (table 6). The incidence of AEs per acin combination therapy was employed showed that the con-100 treatment days was 1.1 events for ciprofloxacin-treated trol combination regimen was also associated with a higher patients, 1.5 events for the control group, and 3.5 events for frequency of AEs (61%). The incidence rate of severe or serious patients receiving ciprofloxacin combination treatment. AEs was low among both the ciprofloxacin group (5%) and the For the ciprofloxacin monotherapy group and the control control group (8%) but higher among the combination therapy group, Ç90% of AEs occurred during the initial 30 days of group (20%) (table 4). study drug exposure. One-half of all AEs appeared within the Most AEs experienced by patients in the ciprofloxacin group first 10 days of therapy (figure 1). were related to the gastrointestinal tract (22%), with nausea,
The incidence rate of drug-related AEs (ADRs) was 23% vomiting, and diarrhea as the leading complaints. Skin (9%), for the ciprofloxacin monotherapy group and 25% for the conurogenital (4%), cardiovascular (3%), and CNS (3%) reactions trol group. When ranked by frequency, digestive system comwere much less frequent. A similar pattern of AEs was also plaints predominated in both groups, followed by skin reactions observed in the control arm (table 5) . No cases of pseudomemand the less common CNS side effects. branous colitis, interstitial nephritis, crystalluria, or retinopathy ADRs were seen more often with ciprofloxacin combination were reported for ciprofloxacin recipients or control drugtherapy (45%) than with ciprofloxacin monotherapy but not treated patients.
when compared with control arms in trials of ciprofloxacin combination therapy (36%). These higher rates of ADRs are undoubtedly a reflection of the more serious underlying condi- control group. For two patients in the control group, death was ganisms rarely require therapy for ú4 weeks. As there is abundant safety information available on ciprofloxacin treatment up partially caused by bacterial infection. No specific information to 1 month, we chose to review the AE profile for patients was listed for three ciprofloxacin-treated patients. treated for significantly longer periods. For this meta-analysis, we selected only prospective, conDiscussion trolled studies of therapy that lasted ú30 days. With these criteria, we hoped to reduce the subjectivity and selective reLonger treatment courses are recommended for osteomyeliporting often found in reports of uncontrolled studies. Nevertis, endocarditis, chronic prostatitis, and some less frequently theless, the limitations of our approach are obvious as we are encountered conditions, like malignant external otitis or bruceldealing with very different populations, diseases, and trial delosis. However, even serious infections caused by problem orsigns. In addition, only a few studies collected safety information in a rigorous double-blinded fashion and presented their results in sufficient detail. (5) 9 (12) with AEs for which the frequencies, patterns, and severities Adverse events 8 (2) 9 (3) 3 (4) are similar. In many studies, ciprofloxacin was evaluated as an oral reinterfere with usual activities. Moderate -An AE that interferes with usual activities but may be ameliorated by therapeuplacement for traditional intravenous antibiotic therapy. Gastrointestinal complaints were common in ciprofloxacin-treated tic measures. Severe -An AE that is intense or debilitating and interferes with usual activities. Recovery is usually aided patients but were always reversible and probably not serious. It is interesting that pseudomembranous colitis or Clostridium by therapeutic measures. Discontinuation of study drug administration may be required. Serious -An AE that is fatal, lifedifficile infection was not associated with long-term ciprofloxacin use.
threatening, or disabling or results in hospitalization or prolongation of hospitalization. In addition, congenital anomaly, oc-CNS symptoms, ranging from headache to seizures, and skin reactions in the form of rashes and anaphylactoid reactions currence of malignancy, and AEs resulting from overdose are always considered serious. were the next most common AEs reported with long-term ciprofloxacin use. Few patients had to discontinue ciprofloxacin therapy because of such AEs. A severe AE occurred in an
